mutant-selective pi3k-alpha h1047r inhibitor loxo-783
Generic: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783
mutant-selective pi3k-alpha h1047r inhibitor loxo-783: 1 clinical trial tracked.
mutant-selective pi3k-alpha h1047r inhibitor loxo-783 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mutant-selective pi3k-alpha h1047r inhibitor loxo-783, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
Primary endpoint: Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)
Interventionalopen260 targetStarted 2022-05Completion 2026-1250 sites · Australia, Belgium, Canada, China…Eli Lilly and Company